Senior Director, Regulatory Affairs
United States · senior · $203k-$253k
Summit Therapeutics is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel therapies to treat cancer, with its lead candidate ivonescimab undergoing multiple Phase 3 clinical trials.
Summit Therapeutics Inc. is a biopharmaceutical oncology company committed to the discovery, development, and commercialization of patient-, physician-, caregiver-, and societal-friendly medicinal therapies. The company's mission focuses on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs, particularly in the field of oncology.
Headquartered in Miami, Florida, with additional offices in Palo Alto, California; Princeton, New Jersey; Oxford, UK; and Dublin, Ireland, Summit Therapeutics has positioned itself as a leader in cancer treatment innovation. The company's lead pipeline candidate is ivonescimab, a novel bispecific antibody targeting both PD-1 and VEGF. In January 2023, Summit established a collaboration and license agreement with Akeso, Inc. for ivonescimab, gaining rights to develop and commercialize the therapy in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.
Summit is currently conducting multiple global Phase 3 clinical trials for ivonescimab, including studies in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company has initiated several Phase 3 trials including HARMONi, HARMONi-3, HARMONi-7, and HARMONi-GI3, demonstrating a commitment to advancing oncology treatment options. With a leadership team that has a proven track record in drug development, regulatory approval, and commercialization, Summit is positioning itself for durable growth while maintaining its focus on patient-centered innovation.
Remote hiring signal is inferred from active confirmed-remote job listings.
Summit Therapeutics roles are commonly associated with Biopharma, Cancer Therapeutics, Biologics and Monoclonal Antibodies, Bispecific Antibody Therapeutics, Clinical Stage Drug Development.
United States · senior · $203k-$253k
United States · Open seniority · $205k-$240k
United States · Open seniority · $205k-$240k
Summit Therapeutics was founded in 2003.
Robert Duggan; Maky Zanganeh is the CEO.
Summit Therapeutics operates in the following markets: Biopharma, Cancer Therapeutics, Biologics and Monoclonal Antibodies, Bispecific Antibody Therapeutics, Clinical Stage Drug Development, Clinical Trials (Phase 3), Pharmaceutical Commercialization, Biotech Licensing and Strategic Partnerships, Oncology, and Immuno Oncology.
Summit Therapeutics has 201-500 employees.
Summit Therapeutics has employees in United States.
Yes, Summit Therapeutics is a remote-friendly company.
Summit Therapeutics provides 5 benefit s to their employees.